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iPSC-derived myelinoids to study myelin biology of
humansGraphical abstractHighlightsd A human stem cell-derived organoid model of widespread
and compact myelination
d Recapitulated impaired paranode formation in patient-
derived cultures
d Pharmacological modulation of oligodendrocyte morphology
and global myelin levels
d Blocking synaptic vesicle release leads to hypomyelinationJames et al., 2021, Developmental Cell 56, 1346–1358










James et al. describe a human stem cell-
derived quantitative model of compact
myelination that recapitulates structural
organization of myelinated axons. They
show impaired paranode formation using
patient-derived cells, developmethods to
analyze myelinating oligodendrocyte
morphology and global myelination, and
demonstrate hypomyelination in
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https://doi.org/10.1016/j.devcel.2021.04.006SUMMARYMyelination is essential for central nervous system (CNS) formation, health, and function. Emerging evidence of
oligodendrocyteheterogeneity inhealthanddiseaseanddivergentCNSgeneexpressionprofilesbetweenmice
andhumanssupports thedevelopmentofexperimentally tractablehumanmyelinationsystems.Here,wedevel-
oped human iPSC-derived myelinating organoids (‘‘myelinoids’’) and quantitative tools to study myelination
from oligodendrogenesis through to compact myelin formation and myelinated axon organization. Using
patient-derived cells, we modeled a monogenetic disease of myelinated axons (Nfasc155 deficiency), recapit-
ulating impaired paranodal axo-glial junction formation.We also validated the use of myelinoids for pharmaco-
logical assessment of myelination—both at the level of individual oligodendrocytes and globally across whole
myelinoids—and demonstrated reduced myelination in response to suppressed synaptic vesicle release. Our
study provides a platform to investigate human myelin development, disease, and adaptive myelination.INTRODUCTION
The formation and maintenance of myelin in the central nervous
system (CNS) of humans is a dynamic life-long process (Westlye
et al., 2010; Williamson and Lyons, 2018). Its disruption is associ-
ated with conditions across the life course including neurodeve-
lopmental, psychiatric, and degenerative disorders (Ameis and
Catani, 2015; Back, 2017; Huang et al., 2015; Kang et al., 2013;
Kelly et al., 2018; Nasrabady et al., 2018; Noseworthy et al.,
2000; Wolf et al., 2021). Critically, myelinated axon function re-
quires both myelin wrapping and organization of distinct axonal
subdomains, such as the paranodal axo-glial junction (PNJ) and
the node of Ranvier. Disruption to eithermyelination ormyelinated
axon organization can lead to disease (Back, 2017; Lubetzki et al.,
2020; Smigiel et al., 2018;Wolf et al., 2021). In addition to enabling
efficient nerve conduction (Seidl, 2014) and providing metabolic
support to axons (Simons and Nave, 2015), accumulating exper-
imental evidence has led to the concept of adaptive myelination:
changes in myelin structure in response to neuronal activity1346 Developmental Cell 56, 1346–1358, May 3, 2021 ª 2021 The Au
This is an open access article under the CC BY license (http://creative(Gibson et al., 2014; Mensch et al., 2015; Mitew et al., 2018).
Although human imaging studies have revealed changes in
white matter structure following visuomotor skill learning
(Sampaio-Baptista and Johansen-Berg, 2017), direct cellular ev-
idence of adaptive myelination by human oligodendrocytes has
not yet been shown. Recent studies have also revealed previously
unappreciated heterogeneity in human oligodendrocytes in
health and disease as well as differences in gene expression pro-
files compared with mammalian model organisms, including
mouse (Castelijns et al., 2020; Hodge et al., 2019; J€akel et al.,
2019; Xu et al., 2018). Together, this indicates that development
of human models of myelination that could recapitulate structural
and physiological features of myelin would serve as important
experimental platforms to both better understand human myelin
biology and complement existing models. Recently, human
models of oligodendrogenesis have been reported that demon-
strate oligodendrocyte differentiation in three-dimensional spher-
oids also containing neurons and astrocytes (Kim et al., 2019;
Madhavan et al., 2018; Marton et al., 2019). These models havethors. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
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OPEN ACCESSTechnologybeen used to validate the effects of pro-differentiating com-
pounds and for transcriptional comparison to primary tissue cells.
However, while axonal ensheathment is evident in these models,
structural organization of paranodal and nodal domains is not
recapitulated (Madhavan et al., 2018). In the CNS, nodal assem-
bly is dependent on PNJ formation, which occurs following en-
sheathment and coincides with myelin compaction (Rasband
and Peles, 2015; Susuki et al., 2013; Wiggins et al., 1988). Nodal
organization thus represents the formation of functionally mature
myelinated axons.With respect to oligodendrocyte heterogeneity
and the practicality of generating in vitro systems with mature
myelinated axons, it is noteworthy that studies so far have
focused on generating myelinating oligodendrocytes within fore-
brain-patterned cultures. There is increasing evidence that the
regional identity of developing oligodendrocytes may influence
theirmaturemyelinating properties (Bechler et al., 2018) andmye-
lination of the cortex, particularly of humans is a protracted
process, potentially slowing down experimental interrogation
(Westlye et al., 2010). For example,MBP+ forebrain-derived oligo-
dendrocytes are identified around 17–20 gestational weeks (gw)
in utero but emerge several months before the onset of cortical
myelination (Back et al., 2002; Jakovcevski et al., 2009). In
contrast, the emergence of ventral spinal cord-derived oligoden-
drocytes occurs as early as 10 gw and is followed by the appear-
ance of myelinated fibers up to 4 weeks later (Weidenheim et al.,
1993). It would follow that spinal cord-patterned organoids might
similarly develop mature myelinated axons at a faster rate than
those patterned to the forebrain. Thus, we aimed to establish
an induced pluripotent stem cell (iPSC)-derived, spinal cord-
patterned model of myelin formation that enabled investigation
of myelin development, disease, pharmacological interventions,
and interrogation of activity-regulated myelination in a human
context.
Design
To date, forebrain-patterned organoids demonstrate sparse
myelination and lack appropriately organized myelinated axon
architecture, limiting their use in the mechanistic evaluation of
human myelin physiology in health and disease. Given the elon-
gated gestation time of humans, modeling cortical myelin devel-
opment in vitro has been particularly challenging. However,
spinal cordmyelination precedes cortical myelination in all verte-
brates, and in humans by several months (Weidenheim et al.,
1993). Therefore, to develop a robust iPSC-derived in vitromodel
of myelination, we sought to generate organoids with a ventral
caudal cell fate as the pMN domain of the ventral spinal cord is
the earliest site of oligodendrogenesis. Furthermore, we devel-
oped an automated analysis platform to quantify widespread
compact myelin within myelinoids.
RESULTS
Generation and characterization of iPSC-derived
myelinating organoids
In order to generate human myelinating cultures, we adapted
our previously published protocol for generating iPSC-derived
oligodendrocytes (Livesey et al., 2016; Magnani et al., 2019)
to induce maturation of oligodendrocytes in spinal cord-
patterned, three-dimensional organoids. Briefly, embryoidbodies generated from dual-SMAD inhibition were exposed to
retinoic acid (RA) and smoothened agonist (SAG) to promote
caudalization and ventralization, respectively, before being
treated with PDGF-AA, IGF-1, and T3 to induce oligodendro-
genesis (Livesey et al., 2016). Resulting spheroids contained
an abundance of OLIG2+ cells, demonstrating acquisition of
pMN domain-derived cells as well as NESTIN+ neural precursor
cells, PDGFRa+ oligodendrocyte progenitor cells (OPCs), CNP+
oligodendrocytes, NF-H+ neurons, and GFAP+ astrocytes
(Figures 1B and S1A). To promote myelin formation, 3 weeks
following glial specification, individual spheroids were trans-
ferred onto hydrophilic PTFE-coated cell culture inserts
(Figure 1A) to ensure efficient gas exchange at the air-liquid
interface (Stoppini et al., 1991) and were maintained in myelina-
tion medium. We refer to this step as myelin induction (MI)-0.
Organoids were further cultured and whole mounted or
sectioned for immunocytochemical analysis at 4, 8, and
12 weeks post-MI-0 (MI-4, MI-8, and MI-12), which revealed
widespread areas of axonal ensheathment by CNP+ cells at
MI-12 (Figure 1C). To characterize the regional identity and
cellular composition of these cultures, qRT-PCR of rostrocau-
dal axis genes and immunostaining was next undertaken.
High expression of HOXB5 and HOXB8 was demonstrated,
consistent with a spinal cord identity (Dasen and Jessell,
2009; Nordström et al., 2006; Philippidou et al., 2012). Analysis
of neuronal subtypes at MI-12 revealed the presence of ChAT+
motor neurons and PV+ ISLET1/2 interneurons, demonstrating
differentiation of region-specific cell types (Figures 1D–1G and
S1B) (Alvarez et al., 2005; Hossaini et al., 2011). Reproducibility
of this protocol to generate myelinating organoids from multiple
cell lines is demonstrated in Figure S1C.
Temporal development of myelin formation
Tobegin toanalyze the temporal developmentofmyelination,orga-
noids were stained with CNP at MI-0, MI-4, MI-8, and MI-12.
Whole-organoid imaging revealed an increase in the number of
CNP+ oligodendrocytes between MI-0 and MI-4, followed by
increased CNP+ sheath formation, suggestive of axonal ensheath-
ment, fromMI-8onward (Figure2A).Structuralanalysisof individual
CNP+ oligodendrocytes revealed maturation of cell morphology
from having primarily thin, highly branched non-myelinating pro-
cesses at MI-0 and MI-4 (Figures 2Bi and 2Bii), to the formation
of distinct myelin sheaths from MI-8 onward (Figures 2Biii and
2Biv). Using SOX10,MBP, andCNP to respectively label oligoden-
droglial lineage,myelin sheaths and the cell body and processes of
mature oligodendrocytes (Figure 2C), we found that the proportion
of mature oligodendroglial cells (MBP+CNP+SOX10+/SOX10+),
averaged across three cell lines, was stable between MI-4 and
MI-12 (Figure 2D). However, the proportion of MBP+ oligodendro-
cytes that engaged in myelin formation increased on average
from18%atMI-4 to 69%atMI-12 (Figure 2E).Mature oligodendro-
cytes were further identified by the co-expression of SOX10 and
NOGO-A (Figure S2A). Immunostaining of MBP, NF-H, and MAP2
revealed thatmyelinationwasonly observedonaxonsandnotden-
drites (Figure 2F), and temporal analysis of MBP+ myelin sheaths
showed increasing sheath lengths over time (Figure 2G). We found
thatmyelin was targeted to both ChAT+ and PV+ axons and that in-
dividualoligodendrocytescouldmyelinatebothPVandPV+axons
simultaneously, as was recently shown in the rodent neocortexDevelopmental Cell 56, 1346–1358, May 3, 2021 1347
Figure 1. Generation and characterization of
iPSC myelinoids
(A) Schematic of protocol for generating spinal
cord-patterned organoids.
(B) Representative images of CNP+ oligodendro-
cytes, NF-H+ axons, SOX10+ oligodendroglial cells
and GFAP+ astrocytes at MI-0 (scale bar, 250 mm).
(C) Representative images of CNP+ oligodendro-
cytes, NF-H+ axons, SOX10+ oligodendroglial cells
and GFAP+ astrocytes at MI-12 (scale bar, 250 mm).
(D) Heatmap of qRT-PCR-derived assessment of
rostral and caudal gene expression in MI-0 organo-
ids. Forebrain, LHX2; midbrain, OTX2; hindbrain,
HOXB4; cervical, HOXB5, cervical, HOXB8. 1/ DCt
values are normalized to 18S rRNA expression
levels, n = 3 batch-conversions per cell-line.
(E) Immunostaining of neuronal dendrites, axons,
and cell bodies by MAP2, NF-H, and NEUN,
respectively (scale bar, 25 mm).
(F) Immunostaining of ChAT+ motor neurons (scale
bar, 10 mm).
(G) Immunostaining of ChAT and parvalbumin (PV)
shows differentiation of distinct neuronal subtypes
(scale bar, 25 mm).
See also Figure S1.
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OPEN ACCESS Technology(Zonouzi et al., 2019) (Figures 2H, 2I, and S2C). In order to charac-
terize the spatial distribution of myelin at MI-12, sections frommul-
tipleorganoidscorresponding tosuperficial anddeepareasof each
organoid were stained with MBP. Distribution analysis of MBP+
pixels revealed that myelin was predominantly found in the periph-
eral areasof each organoid,which coincidedwith dense orientated
tractsofNF-H+axons (FiguresS2C–S2G).Aschematic representa-
tionof thedistributionofmyelinand its temporaldevelopment in this
model is shown in Figure S2H.Structural organization of myelinated axons and myelin
compaction
Myelin thickness and the structural organization of myelinated
axons into discrete subdomains can be used to assess the
maturity of myelinated axons. To assess myelinated axon organi-
zation, we carried out immunostaining analyses of CASPR, CLAU-
DIN-11, ANKYRIN-G, as well as both NEUROFASCIN-155
(Nfasc155) and -186 (Nfasc186) localization using a pan-Neuro-
fascin antibody. Figure 3A shows widespread accumulation of
CASPR at the distal ends of myelin sheaths in MI-12 organoids
and correct assembly and distribution of PNJs and nodes of
Ranvier (Figure 3B) along distinct myelinated axons (Rasband
and Peles, 2015). We next performed toluidine blue staining,
which revealed widespread compact myelin in MI-12 organoids
(Figure 3C). Using transmission electron microscopy, we
confirmed the formation of compactly wrapped myelin lamellae
in organoids derived from multiple cell lines (Figure 3D). Further-
more, g-ratio analysis of myelinated axons revealed comparable1348 Developmental Cell 56, 1346–1358, May 3, 2021myelin thickness aroundaxons inour organoids to that seen in vivo
(mean g-ratio = 0.75 ± 0.09) (Figure 3E) (Hildebrand and Hahn,
1978). Therefore, oligodendrocytes in our organoids demonstrate
compact myelin formation andmyelinated axon organization, and
thus, we refer to these myelinating organoids as myelinoids.Nfasc155–/– patient-derived myelinoids recapitulate
disease pathology of disordered myelinated axon
organization
Having established a reliable system to study human myelination
and myelinated axon organization, we next determined whether
myelinoids generated from iPSCs (two independent clones)
derived from a patient with a mutation in a major component of
the PNJ would result in abnormal myelinated axon organization.
A previously described nonsense mutation in the gene encoding
Neurofascin (NFASC) cell adhesionmolecules results inpremature
terminationof theglial-expressedNfasc155product (Smigiel et al.,
2018) (Figure S3A). The Nfasc155 protein is the glial component of
the PNJ inmyelinated fibers, and its loss inmice causesdisruption
of this adhesive junction (Sherman et al., 2005; Tait et al., 2000).
Nfasc155/ patient-derived myelinoids demonstrated compara-
ble levels of neuronal and glial differentiation to controlmyelinoids.
Patient-derived myelinoids, as expected, consisted of neurons
(ChAT+ and PV+) and GFAP+ astrocytes (Figures 4A–4C) and the
proportion of oligodendroglial cells (SOX10+/DAPI+) as well as
the proportion of mature oligodendroglial cells (MBP+CNP+/
SOX10+) showed no differences to control myelinoids (Figures
4D–4F). Importantly, widespread myelin formation was evident in
(legend on next page)
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Figure 3. Structural organization of myelin-
ated axons and myelin compaction
(A) Representative image of MBP and CASPR im-
munostaining at MI-12 (scale bar, 25 mm).
(B) Paranodal and nodal assembly in MI-12 myeli-
noids: CASPR and CLAUDIN-11 highlight PNJ for-
mation and ANKYRIN-G highlights node formation.
Pan-Nfasc identifies both Nfasc186 at the node and
Nfasc155 at the paranode. White dotted lines mark
these boundaries. Each pair of figures are from
differentmyelinated axons. Scale bars, 5 mm (CASPR
and CLDN-11) and 2 mm (ANK-G and pan-Nfasc).
(C) Toluidine blue staining of MI-12 myelinoids re-
veals presence of compact myelin (scale bar, 5 mm).
(D) Representative TEM images of compactly
myelinated axons at MI-12 (scale bars for Di, Dii,
Div, and Dv, 1 mm, scale bars for Diii and Dvi,
500 nm).
(E) Scatterplot of axon diameter against g-ratio
(axon diameter divided by fiber diameter) with a
logarithmic regression curve (124 axons from 6
myelinoids across distinct conversions from MI-8
onward).
ll
OPEN ACCESS TechnologyNfasc155/ patient-derived myelinoids (Figure 4G) as found pre-
viously inmice (Shermanetal., 2005). ToassessPNJandnode for-
mation, myelinoids were stained with pan-Neurofascin as well as
CASPR and ANKYRIN-G. While expression of Neurofascin at the
node of Ranvier and ANKYRIN-G localization were comparable
between Nfasc155/ myelinoids and controls, we identified a
lackofparanodal localizationofbothglialNeurofascin and itsbind-
ing partner, CASPR (Figures 4H and 4I) across two independent
clones of the Nfasc155/ iPSC line (clone 1 and clone 2). These
data show that iPSC myelinoids can be used to model disorders
of myelinated axon organization.Figure 2. Temporal development of myelin formation in iPSC myelinoids
(A) Representative images of myelin development between MI-0 and MI-12 (scale bar, 250 mm).
(B) Representative images of oligodendrocyte morphology between MI-0 to MI-4 (Bi and Bii) and MI-8 to M
(C) Representative image of SOX10+CNP+MBP+ oligodendrocytes in MI-12 myelinoids (scale bar, 25 mm).
(D) The proportion of mature oligodendroglial cells (MBP+CNP+/SOX10+) was stable between MI-4 and M
change). Two images were taken per myelinoid from n = 22 (MI-4), 24 (MI-8), and 29 (MI-12) myelinoids ac
(E) The proportion of mature MBP+CNP+ oligodendrocytes engaged in myelination increased by 4-fold betw
0.001); generalized linear mixed model (GLMM) with time point as fixed effect and unique myelinoid ID as r
from n = 22 (MI-4), 24 (MI-8), and 29 (MI-12) myelinoids across 3 cell lines (3–5 batch-conversions each).
(F) Immunostaining of MBP, NF-H, and MAP2 shows colocalization of myelin only on NF-H+ axons (scale b
(G) Frequency distribution of MBP+ myelin sheath lengths between MI-4 and MI-12. Myelin sheath length in
44% to 60%; p < 0.001); GLMMwith time point as fixed effect and unique myelinoid ID as random effect, n =
from 5 myelinoids (MI-8), 1,083 sheaths from 5 myelinoids (MI-12).
(H) Representative images of myelinated ChAT+ axons (white arrows), scale bar, 10 mm.
(I) Representative images of myelinated PV+ axons (white arrows), scale bar, 10 mm.
Boxplots show the medians, interquartile ranges and Tukey-style whiskers that extend to 1.5 tim
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.
1350 Developmental Cell 56, 1346–1358, May 3, 2021Myelinoids predictably respond to
pharmacological cues at both
individual cell and whole-myelinoid
levels
We next assessed whether human myeli-
nation could be pharmacologically manip-
ulated in myelinoids and thus aimed to
develop tools to quantify myelin changes
at both the level of individual cells andglobally across whole myelinoids. First, we traced individual
myelin sheaths per cell to evaluate single oligodendrocyte
morphology. Colocalization of CASPR at the distal ends of
manually traced CNP+ myelin sheaths provided confidence
that we were accurately measuring individual myelin sheaths
(Figures 5A and 5B). We observed on average 92% ± 4.8% of in-
ternodes at MI-12 had CASPR+ PNJs (240 internodes across 6
myelinoids from 4 batch-conversions), demonstrating wide-
spread paranodal organization. Under basal conditions and
averaged across myelinoids derived from independent cell lines,
we found that myelinating oligodendrocytes at MI-12 generatedI-12 (Biii and Biv; scale bar, 10 mm).
I-12 at 18.1% (linear mixed effects regression, no
ross 3 cell lines (3–5 batch-conversions each).
een MI-4 and MI-12 (95% CI: 3.42- to 4.89-fold; p <
andom effect. Two images were taken per myelinoid
ar, 25 mm).
creased by 52% between MI-4 and MI-12 (95% CI:
1,061 sheaths from 6myelinoids (MI-4), 754 sheaths
es the interquartile range. n.s. = not significant,
Figure 4. Nfasc155–/– patient-derived myelinoids recapitulate disease pathology of disordered myelinated axon organization
(A) Immuno-staining of neuronal dendrites, axons, and cell bodies in Nfasc155/ MI-12 myelinoids by MAP2, NF-H, and NEUN respectively (scale bar, 25 mm).
(B) Immunostaining of ChAT+ and PV+ neurons in Nfasc155/ MI-12 myelinoids (scale bar, 25 mm).
(C) Immunostaining of DAPI and GFAP+ astrocytes in Nfasc155/ MI-12 myelinoids (scale bar, 25 mm).
(D) Representative image of cryosectioned Nfasc155/ MI-12 myelinoid stained with DAPI, MBP, CNP, and SOX10 (scale bar, 25 mm).
(E) Analysis of the proportion of SOX10+ oligodendroglial cells showed no difference between Ctrl and Nfasc155/ MI-12 myelinoid cryosections (GLMM with
cell-line as fixed effect and unique myelinoid ID as random effect); n = 3 myelinoids each.
(F) Analysis of the proportion of mature MBP+ oligodendroglial cells showed no difference between Ctrl and Nfasc155/ MI-12 myelinoid cryosections (GLMM
with cell-line as fixed effect and unique myelinoid ID as random effect, n = 3 myelinoids each.
(G) Representative image of Nfasc155/ patient-derived myelinoid at MI-12 (scale bar, 250 mm).
(H) Representative images of pan-Nfasc, CASPR andMBP across twoCtrl cell lines and two independently generatedNfasc155/ cell-lines (clone 1 and clone 2)
at MI-12.Nfasc155/myelinoids lack paranodal neurofascin expression and demonstrate disrupted PNJ formation. Axonally expressed neurofascin at the node
remains intact (5–10 nodes analyzed per condition from < 3 myelinoids each; scale bar, 2 mm).
(I) Representative images of ankyrin-G, CASPR and MBP across two Ctrl cell-lines and two independently generated Nfasc155/ cell-lines at MI-12. ANK-G
expression further demonstrates that nodal assembly is preserved inNfasc155/myelinoids (5–10 nodes analyzed per condition from < 3myelinoids each; scale
bar, 2 mm).
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Figure 5. Myelinoids predictably respond to
pharmacological cues at both individual cell
and whole-myelinoid levels
(A) Representative image of tiled area for tracing
individual myelin sheaths per cell (scale bar,
100 mm).
(B) Manual tracing of CNP+ myelin sheath lengths.
CASPR+ PNJs (red arrows) precisely overlap the
distal ends of manually tracedmyelin sheath lengths
(magenta) (scale bar, 100 mm).
(C) Analysis of sheath number per cell (hPSC1:
mean 12.5 ± 8.5 sheaths, hPSC2: 11.3 ± 5.1
sheaths, hPSC3: 12.3 ± 7.3 sheaths). n = 211 cells
across 17 myelinoids (hPSC1), 110 cells across 9
myelinoids (hPSC2), and 90 cells across 9 myeli-
noids (hPSC3) from 2–5 conversions each.
(D) Analysis of mean sheath length per cell (hPSC1:
mean 93.0 mm ± 29.8 mm, hPSC2: 85.6 mm ±
20.4 mm, hPSC3: 67.5 mm ± 28.5 mm). n = 211 cells
across 17 myelinoids (hPSC1), 110 cells across 9
myelinoids (hPSC2), and 90 cells across 9 myeli-
noids (hPSC3) from 2–5 conversions each.
(E) Percentage frequency distribution of myelin
sheath lengths at MI-12. n = 211 cells across 17
myelinoids (hPSC1), 110 cells across 9 myelinoids
(hPSC2), and 90 cells across 9 myelinoids (hPSC3)
from 2–5 conversions each.
(F) Skeletonized CNP+ myelin sheaths of individual
cells from Ctrl and blebbistatin-treated cultures
(scale bar, 25 mm).
(G) Sheath number per cell was increased in bleb-
bistatin-treated cultures by 44.5% compared to Ctrl
(95% CI: 10% to 89%; p = 0.007); GLMM with
treatment as fixed effect and unique myelinoid ID
and batch-conversion as random effects; n = 94
cells from 7 myelinoids (Ctrl) and 60 cells from 6
myelinoids (blebb) across 2 conversions.
(H) Mean sheath length per cell was decreased in
blebbistatin-treated cultures by 24% compared to
Ctrl (95% CI: 10% to 35%; p < 0.001); GLMM with
treatment as fixed effect and unique myelinoid ID
and batch-conversion as random effects; n = 94
cells from 7 myelinoids (Ctrl) and 60 cells from 6 myelinoids (blebb) across 2 conversions.
(I) Representative images demonstrating automated segmentation of MBP+ myelin sheaths at a particular Z-step. MBP expression is shown in greyscale and
segmented objects overlaid in color.
(J) Automated analysis of myelin volume normalized to NF-H intensity over time revealed an overall 8-fold increase betweenMI-4 andMI-8 (95%CI: 3- to 24-fold;
p = 0.006) and a 15-fold increase between MI-4 and MI-12 (95% CI: 6- to 40-fold; p < 0.0001); GLMM with timepoints as fixed effects and batch-conversion and
cell-lines as random effects. n = 19 (MI-4), 13 (MI-8) and 34 (MI-12) myelinoids across three cell-lines (2–7 conversions each).
(K) Representative images of MBP expression in Ctrl and BDNF-treated whole-mounted myelinoids (scale bar, 250 mm).
(L) Automated analysis of myelin volume normalized to NF-H intensity revealed a 2.09-fold increase in BDNF-treated myelinoids (95% CI: 1.13-fold to 2.74-fold;
p = 0.0024); GLMM with treatment as fixed effect and batch-conversion as random effect). n = 13 (Ctrl) and 13 (BDNF) myelinoids from 3 conversions each.
(M) Automated analysis of NF-H intensity showed no change between Ctrl and BDNF-treated myelinoids (GLMM with treatment as fixed effect and batch-
conversion as random effect). n = 13 (Ctrl) and 13 (BDNF) myelinoids from 3 conversions each.
Boxplots show the medians, interquartile ranges and Tukey-style whiskers that extend to 1.5 times the interquartile range. n.s. = not significant,
**p < 0.01, ***p < 0.001. See also Figure S4.
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cell of 87 mm ± 27.9 mm (Figures 5C and 5D). A frequency distri-
bution curve ofmyelin sheath lengths is shown in Figure 5E.Mye-
linoids treated with blebbistatin, a non-muscle myosin II inhibitor
and knownmodulator of myelin structure (Wang et al., 2008), be-
tween MI-0 and MI-12 exhibited a 44.5% increase in myelin
sheath number per cell (Figures 5F and 5G). Mean sheath length
per cell was reduced by 24% (Figure 5H). These findings match
those found in studies of rodent oligodendrocytes (Wang et al.,
2008) and show that the myelinating profile of individual oligo-1352 Developmental Cell 56, 1346–1358, May 3, 2021dendrocytes can be modulated pharmacologically. In order to
measure global levels of myelination, we developed an auto-
mated method of image acquisition and analysis using an Im-
ageXpress microconfocal with MetaXpress software that
permitted unbiased 3D quantification of myelin volume and
axonal density (Figures 5I and 5J). Selective segmentation of
myelinated axons is demonstrated in Figure 5J. We observed
that myelin volume was closely correlated with axonal density
(assessed by quantifying NF-H+ intensity) (R2 = 0.6, Figure S4)
as has been shown previously (Almeida et al., 2011; Lundgaard
Figure 6. TeNT suppresses human myelina-
tion
(A) Skeletonised CNP+ myelin sheaths of individual
cells from Ctrl and TeNT-treated cultures (scale bar,
25 mm).
(B) Sheath number per cell in Ctrl and TeNT-treated
myelinoids. There was an overall 20% reduction in
sheath number per cell in TeNT-treated myelinoids
(95% CI: 6% to 31%; p = 0.006); GLMM with
treatment as fixed effect and unique myelinoid ID
and cell-line as random effects. hPSC1: 19%
reduction (95% CI: 3% to 33%; p = 0.02); hPSC2:
23% reduction (95%CI: 0.4% to 40%; p = 0.04); n =
314 cells from 23 myelinoids (Ctrl) and 290 cells
from 20 myelinoids (TeNT) across two cell-lines and
5 conversions.
(C) Mean sheath length per cell in Ctrl and TeNT-
treated myelinoids. There was an overall 14% in-
crease inmean sheath length per cell in TeNT-treated
myelinoids (95% CI: 4% to 21%; p < 0.01); GLMM
with treatment as fixedeffect and uniquemyelinoid ID
and cell-line as random effects). hPSC1: 12.5% in-
crease (95% CI: 2% to 23%; p = 0.018); hPSC2: no
statistical difference; n = 314 cells from23myelinoids
(Ctrl) and 290 cells from 20 myelinoids (TeNT) across
two cell-lines and 5 conversions.
(D) Nearest neighbor analysis shows no change in
oligodendrocyte density between Ctrl and TeNT-
treated myelinoids (GLMM with treatment as fixed
effect and uniquemyelinoid ID and cell-line as random effects). n = 49 cells from 12myelinoids (Ctrl) and 51 cells from 9myelinoids (TeNT) across two cell-lines and 4
conversions.
(E) Representative images of Ctrl and TeNT-treated myelinoids (scale bar, 250 mm).
(F) Automated analysis ofmyelin volume normalized toNF-H intensity demonstrated an overall reduction of 38% in TeNT-treatedmyelinoids (95%CI: 4% to 52%; p =
0.017); GLMMwith treatment as fixed effect and individual batch-conversions and cell-lines as random effects). hPSC1: 35% reduction (95% CI: 1.4% to 57% p =
0.043); hPSC2: 65% reduction (95% CI: 4.1% to 87.3%; p = 0.041); n = 29 (Ctrl) and 22 (TeNT) myelinoids across two cell lines and 5 conversions.
(G) Automated analysis of NF-H intensity (GLMMwith treatment as fixed effect and individual batch-conversions and cell-lines as random effects, no change. n = 29
(Ctrl) and 22 (TeNT) myelinoids across two cell lines and 5 conversions.
Boxplots show the medians, interquartile ranges and Tukey-style whiskers that extend to 1.5 times the interquartile range. n.s. = not significant, *p < 0.05. See also
Figure S5.
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ume across myelinoids, we normalized it to the integrative NF-H
intensity measure for each myelinoid. Temporal analysis of
myelin volume—normalized to NF-H intensity—demonstrated
significantly increased myelin volume over time (Figure 5J). To
potentiate myelin volume, myelinoids were treated with BDNF,
which has previously been shown to enhance myelin formation
(Lundgaard et al., 2013; Xiao et al., 2010). BDNF-treated myeli-
noids demonstrated a 2-fold increase inmyelin volume—normal-
ized to NF-H intensity—without affecting NF-H intensity (Figures
5K–5M), indicating that widespread effects on human myelina-
tion can be assessed using our model.
Tetanus toxin (TeNT) suppresses human myelination
Numerous cellular and animal models have shown that oligoden-
drocytes modulate myelin structure in response to changes in
neuronal activity (Gibson et al., 2014; Hines et al., 2015; Mensch
et al., 2015; Mitew et al., 2018; Wake et al., 2011). No evidence,
to date, has been reported of changes to human myelination per
se in response to altered neuronal activity. To address this, we
sought to assess whether in vitro human myelination could be
suppressed by blocking synaptic vesicle (SV) release. Tetanus
toxin (TeNT) blocks SV release via proteolytic cleavage of synap-tobrevin 1/2 (VAMP2), thereby suppressing both spontaneous as
well as action potential-evoked SV release (Kim et al., 1984),
including in stem cell-derived neurons (Beske et al., 2016).
TeNT suppresses myelin formation both in vitro and in vivo in
model systems (Hines et al., 2015; Mensch et al., 2015; Wake
et al., 2011) and has been shown to reduce the number of myelin
sheaths made by individual oligodendrocytes in the developing
spinal cord of zebrafish, via a non-cell-autonomous mechanism
(Mensch et al., 2015). To examine the impact of TeNT on human
myelination, myelinoids were chronically treated with TeNT for
12 weeks at a concentration previously shown to suppress SV
exocytosis (3nM; Morton et al., 2015). We found that TeNT-
treated myelinoids, derived from two independent cell lines,
showed a 20% reduction in the number of sheaths made by in-
dividual oligodendrocytes (Figures 6A and 6B). Concomitantly,
we observed an increase in mean sheath length per cell
(Figure 6C). A nearest neighbor analysis (Figure S5A) was per-
formed to determine CNP+ oligodendrocyte density, which was
found to be unchanged between Ctrl and TeNT-treated myeli-
noids (Figure 6D). To determine whether TeNT might directly
affect oligodendrocyte morphology, noting that oligodendro-
cytes express SNARE proteins and that VAMP2 disruption alters
oligodendrocyte morphogenesis (Sloane and Vartanian, 2007),Developmental Cell 56, 1346–1358, May 3, 2021 1353
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14 days in the presence or absence of TeNT (Figure S5B). Sholl
analysis of MBP+ oligodendrocytes at day 14 showed no differ-
ence in oligodendrocyte branching or total outgrowth between
Ctrl and TeNT-treated cultures (Figures S5C and S5D), suggest-
ing that TeNT-induced hypomyelination does not occur via a
cell-autonomous mechanism. Finally, to determine whether
reduction in sheath number per cell would result in a global
reduction in myelination, we performed automated quantifica-
tion of myelin volume in TeNT-treated myelinoids. We found a
38% reduction in myelin volume relative to NF-H intensity in
TeNT-treated myelinoids (Figures 6E and 6F). NF-H intensity
was not affected by TeNT treatment, indicating that the effect
onmyelination was not due to general disruption to axonal devel-
opment (Figure 6G). Thus, reduced vesicular release in human
myelinating cultures suppresses myelin development, providing
an opportunity for in-depth cellular, molecular, and functional an-
alyses of human adaptive myelination.
DISCUSSION
We describe a model of myelination that recapitulates the three-
dimensional architecture of myelinated axons for investigation of
human myelin biology. Recognition that oligodendrocytes and
myelin have multiple roles beyond saltatory conduction and are
pivotal players in thedynamic cellular interplayof theCNS inhealth
and disease underlines the importance of humanmodels of oligo-
dendrocyte-neuron interaction. This is emphasizedby thegrowing
numberof conditionsacross the life coursewheredysregulationor
loss of myelin is believed to play an important role (Fields and
Bukalo, 2020; Mot et al., 2018; Nave and Ehrenreich, 2014).
Human stem cell-derived forebrain-patterned organoid models
have previously shown oligodendrocyte maturation through mye-
lination (Madhavan et al., 2018; Marton et al., 2019; Kim et al.,
2019), but such systems lack widespread compact myelination
and evidence of myelinated axon organization into functional do-
mains.We hypothesized that the limited myelination and absence1354 Developmental Cell 56, 1346–1358, May 3, 2021of paranodal and nodal structures in these studies may reflect
their rostral regional identity and the later developmental acquisi-
tion of myelin in the brain compared with caudal structures (Back
et al., 2002; Jakovcevski et al., 2009). Accordingly, we generated
ventral spinal cord-patterned organoids to mimic the compara-
tively accelerated development of spinal cord myelination
(Weidenheimet al., 1993). Table 1 summarizes key differences be-
tween published protocols. It would thus be of considerable inter-
est toevaluatewhether forebrain-patternedorganoidpreparations
develop features of more complete myelination with prolonged
culture. Regionally distinct human myelinating systems provide
an opportunity to investigate cortical and spinal cord oligodendro-
cyte functional heterogeneity as well as model myelin diseases
that show anatomical variation in predilection (Table 1). The use
of cell culture inserts that maintain organoids at an air-liquid inter-
face is also of interest (Table 1). These conditions provide
enhanced oxygen availability and tissue survival (Klasvogt et al.,
2017). Indeed, cerebral organoids culturedatanair-liquid interface
demonstrate improved survival and outgrowth of neurons
(Giandomenicoet al., 2019). Increasedoxygenationmayalso facil-
itate enhancedmetabolic support toOPCsandpre-myelinatingol-
igodendrocytes as the shift from oxidative phosphorylation to
glycolysis does not occur until after developmental myelination is
complete (F€unfschilling et al., 2012; Rao et al., 2017). While our
study establishes a reproducible platform for the evaluation of hu-
man myelin biology, we also note technical considerations for
future development and application of themodel. A degree of bio-
logical variability between cell lines and batches was seen in our
data, which can be explicitly modeled as random effects, as was
performed in this study. Our integrative intensity measures of
NF-H staining could also be further evolved in future work by
adopting analytic methods to account for variation in NF-H+ tract
area and density between myelinoids.
The ability to recapitulate compact myelin formation and
myelinated axon organization allows the study of nodal assem-
bly and disruption in health and disease. Here, we demonstrated
that patient-derived myelinoids recapitulated the key pathology
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OPEN ACCESSTechnologyof Nfasc155 deficiency, namely impaired paranode formation.
Importantly, given that Nfasc155/ mice prematurely die be-
tween P17–P20, investigations into the long-term impact of
Nfasc155 deficiency or other mutations on nodal domain stabil-
ity and axonal health may be well served using iPSC myelinoids
(Pillai et al., 2009; Roche et al., 2014). Furthermore, using an
automated platform of image analysis, the ability to screen for
myelin-related phenotypes across patient-derived myelinoids
as well as pharmacological rescue of myelin phenotypes is a
further application of this model. Several studies have revealed
key pathways and compounds that promote oligodendrocyte
differentiation and myelination (Deshmukh et al., 2013; Early
et al., 2018; Hubler et al., 2018; Mei et al., 2014, 2016). With
further adaptation, such as miniaturization into multi-well plate
format and the use of myelin-specific fluorescent markers,
screening for small molecules that promote human myelination
in iPSC myelinoids represents an important goal.
Multiple lines of accumulating evidence dating back to
in vivo observations in dark reared mice through to optoge-
netic or DREADD-based modulation provide a strong evi-
dence base for neuronal activity-regulated myelination
(Gibson et al., 2014; Gyllensten and Malmfors, 1963; Mitew
et al., 2018). However, whether human myelinating oligoden-
drocytes are capable of responding to changes in neuronal
activity has not been possible to directly study. To begin to
address the effect of neuronal activity on myelination, we
used TeNT to block SV release. Blocking SV release has
been shown to lead to preferential myelin targeting to active
axons and a reduction in internodes per oligodendrocyte
both in vitro and in vivo (Hines et al., 2015; Koudelka et al.,
2016; Mensch et al., 2015; Wake et al., 2011). We demon-
strated that myelinoids exposed to TeNT showed a reduction
in both internode number per oligodendrocyte and a reduction
in global myelin volume that mirrors data obtained from anal-
ogous in vivo experiments of TeNT-expressing zebrafish
(Mensch et al., 2015). Oligodendrocyte density was un-
changed following TeNT exposure in myelinoids, in line with
the minimal effect observed in zebrafish. Furthermore, we
observed differences in the degree by which TeNT affected
sheaths per cell and global myelin volume (20% versus 38%
reduction, respectively) and between the two cell lines. Noting
that automated segmentation is an intensity-based analysis,
these differences may be explained by the capture of addi-
tional myelin sheath dimensions including myelin sheath thick-
ness. Furthermore, as the hypomyelinating effect of TeNT is
dependent on the level of intrinsic neuronal activity in myeli-
noid cultures, variation in basal activity between batches of
myelinoids may add to the differences observed. To compre-
hensively interrogate the influence of activity on myelination, it
would thus be important to examine the effect of systematic
modulation and bidirectional tuning of neuronal activity using
a variety of approaches from cell type-specific expression of
chemogenetic tools to pharmacological manipulation.
Collectively, our demonstration of a robust model of wide-
spread compact myelination with appropriate nodal architecture
establishes a tractable and quantifiable platform for evaluation of
human myelin biology in a tissue-level context. The ability to
assess oligodendrocyte cell biology, cell-cell interactions
and disruption in disease is possible, with the potential forphenotypic screening of myelin development and pharmacolog-
ical interrogation of developmental and activity-dependent
processes.Limitations of the study
As mentioned above, one limitation is that inferences made on
myelin development in this model may not be generalizable due
to the spinal cord identity of myelinoid cultures. As such, their
use in studying myelin development in the context of certain
neurological conditions may be limited. Second, given the
extended time frame over which myelination occurs in this sys-
tem, it can be challenging to optimize the dosing of small
molecules/treatments that influence myelin development or
neuronal activity. This could be improved by the use of cell
type-specific reporters and optogenetic applications. Further-
more, a common limitation of organoid models is that they
lack the full complement and diversity of cell types found in vivo.
Microglia are absent in these organoids and yet play critical
roles in neurodevelopment (Hagemeyer et al., 2017; Li and
Barres, 2018). Several methods to incorporate microglia into
developing organoids have been successful including
patterning of intrinsic cells (Ormel et al., 2018) or transplanta-
tion of exogenously derived cells (Abud et al., 2017; Banerjee
et al., 2020). Application of such methods with iPSC myelinoids
would provide an opportunity to study the role of microglia in
myelin development, degradation, and repair, the role of which
remains largely unknown.STAR+METHODS
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mouse anti-NESTIN Millipore Cat#MAB5326; RRID: AB_2251134
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Matrigel Basement Membrane matrix Scientific Laboratory Supplies Cat#354230
Dispase Thermo Fisher Scientific Cat#17105041
Collagenase Thermo Fisher Scientific Cat#17104019
Iscove’s Modified Dulbecco’s Medium Thermo Fisher Scientific Cat#21980032
F-12 Nutrient Mix Thermo Fisher Scientific Cat#31765-027
SB- 431542 R&D Systems Cat#1614/1
LDN-193189 Merck Cat#SML0559
BSA Europa Bioproducts Cat#EQBAC62




N-acetyl cysteine Sigma Cat#A8199
Antibiotic-Antimycotic Thermo Fisher Scientific Cat#15240062
Retinoic acid Sigma Cat#R2625
FGF-2 PeproTech Cat#450-33
Purmorphamine Sigma Cat#540220
Advanced DMEM/F12 Thermo Fisher Scientific Cat#12634028
N2 Supplement Thermo Fisher Scientific Cat#17502048
B27 Supplement Thermo Fisher Scientific Cat#17504044
GlutaMAX Supplement Thermo Fisher Scientific Cat#35050038
PDGF-AA Peprotech Cat#AF-100-13A
Smoothened agonist Sigma Cat#566660
(Continued on next page)
Developmental Cell 56, 1346–1358.e1–e6, May 3, 2021 e1
Continued




ITS Thermo Fisher Scientific Cat#51500-056
BDNF R&D Systems Cat#248-BD
Blebbistatin Sigma Cat#203390




Paraformaldehyde Agar Scientific Cat#AGR1026
Gluteraldehyde Agar Scientific Cat#R1010
Normal goat serum Vector Laboratories Cat#S1000
OCT-compound Biosystems Cat#14020108926
Toluidine blue Wako Pure Chemical Industries Cat#C.I.52040
Critical commercial assays
RNeasy Mini Kit Qiagen Cat#74106
DyNAmo ColorFlash SYBR DyNAmo
ColorFlash SYBR Green qPCR Kit
Thermo Fisher Scientific Cat#10442308
Worthington Papain Dissociation System Worthington-biochemical Cat#LK003150
Epoxy resin Kit Agar Scientific Cat#Araldite CY212
Experimental models: cell lines
CS02iCTR-n1 Cedars Sinai N/A
CS25iCTR-18n2 Cedars Sinai N/A
SHEF-4 (AXORe004-A) UK Stem Cell Bank N/A
CS00iNK-n1 and -n2 Chandran lab N/A
Oligonucleotides
Primers for Nfasc155 mutation site F:
CACCCTTTTGTCCTGAGCCTT
This paper N/A
Primers for Nfasc155 mutation
site R: ATAGCCCGCATTTGCTACCC
This paper N/A
qPCR primer for 18s F:
GTAACCCGTTGAACCCCATT
This paper N/A
qPCR primer for 18s R:
CCATCCAATCGGTAGTAGCG
This paper N/A
qPCR primer for LHX2
F: ATGCTGTTCCACAGTCTGTCG
This paper N/A
qPCR primer for LHX2
R: GCATGGTCGTCTCGGTGTC
This paper N/A
qPCR primer for OTX2
F: AGAGGACGACGTTCACTCG
This paper N/A
qPCR primer for OTX2
R: TCGGGCAAGTTGATTTTCAGT
This paper N/A
qPCR primer for HOXB4
F: GTGAGCACGGTAAACCCCAAT
This paper N/A
qPCR primer for HOXB4
R: CGAGCGGATCTTGGTGTTG
This paper N/A
qPCR primer for HOXB5
F: CGGGTCAGGTAGCGATTG
This paper N/A
qPCR primer for HOXB5
R: AGCTTCACATCAGCCACGAT
This paper N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Siddhar-
than Chandran (Siddharthan.Chandran@ed.ac.uk).
Materials availability
Unique material generated in this study is available from the Lead Contact with a completed Materials Transfer Agreement.
Data and code availability
Relevant data and code are available from the corresponding author (SC) upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Culture of human iPSCs
The human pluripotent stem cell-lines used in this study were obtained with full Ethical/Institutional Review Board approval by the
University of Edinburgh and validated using standard methods including chromosomal analysis, pluripotency and absence of
plasmid integration. The iPSC lines CS02iCTR-NTn1 (hPSC1, male) and CS25iCTRL-18n2 (hPSC2, male) were obtained from Ce-
dars-Sinai. For the Nfasc155-/- lines, fibroblasts were obtained by RS with ethical approval granted by the Institutional Review Board
of Warsaw Medical University (Smigiel et al., 2018). The CS00iNK-n1 (Nfasc155-/-clone 1, female) and CS00iNK-n2 (Nfasc155
-/-
clone 2,
female) iPSC lines were generated by Cedars-Sinai. The human embryonic stem cell-line SHEF4 (hPSC3, male) was obtained from
the UK Stem Cell Bank. iPSCs were maintained on Matrigel (Scientific Laboratory Supplies)-coated 6-well plates in Essential 8 me-
dium (Thermo Fisher Scientific) at 37 C and 5% CO2. iPSC colonies were passaged by incubating in Dispase (0.5 mg/ml, Thermo
Fisher Scientific)/Collagenase (1 mg/ml, Thermo Fisher Scientific) for 15-25 minutes at 37 C, washed in DPBS and resuspended in
Essential 8 medium before being redistributed in new 6-well plates. Cultures were regularly tested andmaintained mycoplasma free.
These cell-lines have not been authenticated.
METHOD DETAILS
Generation of iPSC myelinoids
iPSC myelinoids were generated by adapting a previously published protocol for the generation of iPSC-derived oligodendro-
cytes (Livesey et al. 2016). Briefly on day 0, iPSC colonies were lifted using Dispase (0.5 mg/ml)/Collagenase (1 mg/ml), washed
in DPBS and transferred to 10 cm dishes to be neuralized as a suspension culture in phase I medium (0.5 x Iscove’s modified
Dulbecco’s medium (Thermo Fisher Scientific), 0.5 x F12 (Thermo Fisher Scientific), 20 mM SB- 431542 (R&D Systems) and
0.1 mM LDN-193189 (Merck), 5 mg/ml BSA (Europa Bioproducts), 1 x chemically defined Lipid concentrate (Thermo
Fisher Scientific), 4.32 mg/ml monothioglycerol (Sigma), 7 mg/ml insulin (Sigma), 15 mg/ml transferrin (Sigma), 1 x Antibiotic-
Antimycotic (Thermo Fisher Scientific) and 1 mM N-acetyl cysteine (Sigma)). On day 7, 1 mM retinoic acid (RA, Sigma) was
added to pattern neurospheres toward a caudal fate (phase II). On day 14, neurospheres were plated onto laminin-coated
dishes to selectively enrich for neural precursor cells (NPCs) by assessing neural rosette formation. On day 17, adheredDevelopmental Cell 56, 1346–1358.e1–e6, May 3, 2021 e3
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(10 ng/ml, PeproTech) and 1 mM purmorphamine (Sigma) in N2/B27 base medium (Advanced DMEM/F12 (Thermo Fisher Sci-
entific), 1 x N2 (Thermo Fisher Scientific), 1 x B27 (Thermo Fisher Scientific), 1 x Glutamax (Thermo Fisher Scientific), 1 x Anti-
biotic-Antimycotic (Thermo Fisher Scientific)) to expand and ventralize neural progenitor cells. After 7 days, neurospheres were
transferred to phase III medium lacking FGF-2 and maintained for a subsequent 2 weeks to induce neuronal and glial differen-
tiation. Next, neurospheres were transferred to oligodendrocyte proliferation medium (N2/B27 base medium plus 10ng/ml FGF-
2 (PeproTech), 20 ng/ml PDGF-AA (PeproTech), 1 mM purmorphamine (Sigma), 1 mM smoothened agonist (SAG, Sigma), 10 ng/
ml IGF-1 (PeproTech), 60 ng/ml T3 (Sigma), 1 x ITS (Thermo Fisher Scientific), 5mg/ml heparin (Sigma)). After 2-4 weeks, myelin
induction (MI) was initiated by transferring individual spheroids (700-1500 mm diameter) onto PTFE-coated Millicell Cell Culture
Inserts (Merck) in 6 well plates using a P200 pipette and maintained in myelination medium thereafter (N2/B27 base medium,
5 mg/ml heparin, 1 x ITS, 10 ng/ml IGF-1, 60 ng/ml T3) at 7.5 % CO2, replacing the medium every 2-3 days. To modulate myelin
sheath number per cell, blebbistatin (10 mM, Sigma) or TeNT (3 nM, Sigma) were added to myelination medium at MI-0 and
maintained throughout the remainder of the culture period. To modulate global myelination, BDNF (10 ng/ml, R&D Systems)
was added to the medium between MI-0 and MI-12 and the same TeNT-treated spheres were used as for single cell analysis.
Four, eight or twelve weeks after being placed on cell culture inserts, myelinoids were fixed by immersing inserts in 4 % para-
formaldehyde (PFA, Agar Scientific) for 2 hours at room temperature (RT) before being washed in PBS (2 x 30 minutes, RT) and
kept at 4 C before further processing.
Dissociated myelinoid cultures
MI-0 myelinoids were dissociated using the Worthington Papain Dissociation System (LK003150) as described previously (Magnani
et al., 2019; Vasistha et al., 2019). Cells were plated at 20-30,000 cells per 0.3cm on coverslips coatedwith 1/100 dilutedMatrigel (BD
Biosciences), 20 mg/ml Fibronectin (Sigma), and 10 mg/ml Laminin (Sigma) and cultured with the samemyelinationmedium as above.
TeNT (3nM)was supplemented in themedia fromday 1 onwards. Cells were fixed at day 14 by immersing in 4%PFA for 20minutes at
RT, before being washed in PBS and stained for MBP and DAPI.
Immunostaining of whole-mounted myelinoids
Cell counts, manual tracing of myelin sheaths per cell and automated measurements of myelin volume were performed on whole-
mounted myelinoids. For immunostaining, membranes containing myelinoids were cut out and transferred to a 24-well-plate con-
taining PBS. Cells were permeabilized in 0.25 % triton-X-100 in PBS for 40 minutes and blocked in blocking solution (10 %
normal goat serum (Vector Laboratories) + 0.25 % triton-X-100) for 2 hours at RT. CNP immunostaining required an additional
step of antigen retrieval by incubating myelinoids in citrate buffer (pH 6) at 95 C for 20 minutes followed by a further hour in
blocking solution. Primary antibodies were diluted in blocking solution and incubated overnight at 4 C. We used rabbit anti-
OLIG2 (Abcam, 1:200), mouse anti-NESTIN (Merck, 1:300), Cy3 conjugated anti-GFAP (Sigma, 1:500), mouse anti-NogoA
(R&D systems, 1:100), goat anti-ChAT (Millipore, 1:250), mouse anti-Isl1/2 (DSHB, 1:100), mouse anti-NeuN (Millipore, 1:500),
mouse anti-MAP2 (Sigma, 1:200), rabbit anti-PV (SWANT, 1:500), rabbit anti-SOX10 (Abcam, 1:500), rabbit anti-PDGFRa (Cell
Signalling, 1:200), rat anti-MBP (Abcam, 1:100), mouse anti-CNP (Atlas, 1:2000), chicken anti-NF-H (Biolegend, 1:10,000), rabbit
anti-CASPR (Abcam, 1:1000), rabbit anti-CLAUDIN-11 (Thermo Fisher, 1:75), mouse anti-ANKYRIN G (UC Davis/NIH NeuroMab,
1:100), chicken anti-Neurofascin (Thermo Fisher, 1:100). The next day, myelinoids were washed (3 x 20 minutes) in PBS + 0.1 %
Tween-20 (PBS-T). Secondary antibodies were diluted in blocking solution and incubated for 2 hours at RT. We used Alexa Fluor
goat anti-mouse IgG1, goat anti-mouse IgG2b, goat anti-rabbit IgG, goat anti-chicken IgY, donkey anti-goat IgG, donkey anti-rat
and donkey anti-rabbit (all from Abcam, all 1:1000). Myelinoids were incubated with DAPI (Sigma, 1:50,000) for 10 minutes,
washed in PBS and mounted onto microscope slides (Thermo Scientific) with FluorSave (Calbiochem) and No. 1.5 coverslips
(Thermo Scientific).
Cryopreservation and immuno-staining
To assess myelin distribution, ensheathment of different neuronal subtypes and PNJ and nodal assembly, membranes containing
myelinoids were cut out and incubated in 30 % sucrose in PBS at 4 C for at least 24 hours. Next, myelinoids were transferred
into moulds containing a 1:1 solution of 30 % sucrose and OCT-compound (Biosystems) and cryopreserved by placing moulds in
a bath of isopentane over dry ice. 10 mm cryosections were cut using a Leica cryostat, mounted onto superfrost-plus glass slides
(VWR International) and stored at -20 C. Immuno-staining was performed by bringing slides to RT and washing in PBS (3 x
10 min). Sections were permeabilised in 0.25 % triton-X-100 for 15 minutes before being blocked in blocking solution for 2 hours.
Primary antibodies (see above) were diluted in blocking solution and incubated in a humid chamber overnight at RT. Sections
were washed in PBS-T (3 x 10 min) and incubated with secondary antibodies diluted in blocking solution for 2 hours at RT. Sections
were stained with DAPI for 5 minutes, washed in PBS and mounted with FluorSave.
Image acquisition
A Zeiss 710 confocal was used for the following: for cell counts, two z-stacks per myelinoid (whole-mounted) were acquired
with a 40X (1.3 NA) objective; for manual tracings of individual oligodendrocytes, a 40X objective was used to create tiled
z-stacks (typically 3x4 tiles, 20 mm z-depth with 0.25 mm z-steps), and a minimum of 5 cells per myelinoid were measured.e4 Developmental Cell 56, 1346–1358.e1–e6, May 3, 2021
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volume, an ImageXpress micro confocal was used. Low magnification (4X) scans of each microscope slide were taken, and
acquisition areas were drawn around each myelinoid. 12 mm z-stacks (1 mm z-step) beginning at the superficial edge of
each acquisition area were acquired using a 20X plan Apo objective, in 42 mm pin hole confocal mode, and with 10% overlap
for stitching. A custom macro was written in Fiji/ImageJ to stitch images together using the Grid/Collection stitching plugin
(Preibisch et al., 2009).
Transmission electron microscopy
To demonstrate myelin compaction, myelinoids were fixed in phosphate buffer (PB) containing 4 % PFA and 2 % glutaraldehyde
(Agar Scientific) for 2 hours, post-fixed in 0.1 % glutaraldehyde for 24 hours at 4 C and washed in 0.1 M PB (2 x 15 min). Samples
were transferred to 1%OsO4 in 0.1 M PB for 45 min at RT, washed in 0.1 M PB and then dehydrated in increasing concentrations of
EtOH for 15 minutes each (50 %, 70 %, 90 %, 100 % x 3). The Epoxy Resin (Araldite) kit (Agar Scientific) was used for embedding
samples. Briefly, samples were incubated in a 1:1 mix of Araldite-DDSA:acetone for 1 hour then transferred to Araldite-DDSA for
overnight incubation before being cured in Araldite embedding mix at 60 C for 48 hours. For toluidine blue staining, 1 mm semithin
sections were cut, placed on Polysine slides (VWR) and flattened by rotating the slide on a heat plate. The slide was then flooded with
toluidine blue (Wako, 5% in a Borax solution) and heated again until vapours evolved. The slides were washed in water, mounted with
FluorSave and imaged on a Zeiss Observer microscope. For Transmission electron microscopy, ultrathin sections, 60 nm thick, were
cut, stained in Uranyl Acetate and Lead Citrate then viewed using a JEOL JEM-1400 Plus TEM. Images were captured on a GATAN
OneView camera.
PCR amplification of Nfasc155
To confirm the presence of the homozygous NFASC mutation in patient-derived iPSCs, primers flanking the rs755160624 mutation
site were generated (F: 5’ CACCCTTTTGTCCTGAGCCTT 3’; R: 5’ ATAGCCCGCATTTGCTACCC 3’) and PCR products from
Nfasc155-/- and Ctrl iPSCs were sent for Sanger Sequencing (SourceBioscience).
Quantitative RT-PCR
qRT-PCRwas performed according to a previously described protocol (Bilican et al., 2014). Briefly, 250ng of total RNA collected from
MI-0 myelinoids using an RNeasy Mini Kit (Qiagen) was used to synthesise cDNA using the DyNAmoTM cDNA synthesis kit (Thermo
Fisher Scientific). Real-time quantitative PCR reactions were prepared using the DyNAmo ColorFlash SYBRGreen qPCR kit (Thermo
Fisher Scientific) and performed on a CFX96 system (BioRad). The primers used for Figure 1D are as follows:
18s F: GTAACCCGTTGAACCCCATT, 18s R CCATCCAATCGGTAGTAGCG: LHX2 F: ATGCTGTTCCACAGTCTGTCG, LHX2 R:
GCATGGTCGTCTCGGTGTC, OTX2 F: AGAGGACGACGTTCACTCG, OTX2 R: TCGGGCAAGTTGATTTTCAGT, HOXB4 F: GTGAGCA
CGGTAAACCCCAAT, HOXB4 R: CGAGCGGATCTTGGTGTTG, HOXB5 F: CGGGTCAGGTAGCGATTG, HOXB5 R: AGCTTCACATCAG
CCACGAT,HOXB8F:CAGCTCTTTCCCTGGATGC,HOXB8R:ATAGGGATTAAATAGGAACTCCTTCTC.Datawasobtainedbypooling5
myelinoids per batch-conversions (n=3 batch-conversions per cell-line). 1/DCt values were obtained by normalizing to 18S rRNA expres-
sion levels.
QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis
Cell countswere performedusing the built-in FIJI plugin, Cell Counter.Manual tracing ofmyelin sheathswasperformed using theSim-
ple Neurite Tracer plugin (Longair et al., 2011). Overlaying manual tracings of myelin sheaths with CASPR immuno-staining from the
same region of interest confirmedwewere accuratelymeasuring sheath length (Figure 5B). Nearest neighbor analysis was performed
todetermine oligodendrocyte density by plotting a 100mmradius circle around individual cells and counting the number ofmyelinating
oligodendrocytes within that area (Figure S5A). Sholl analysis on MBP+ cells from dissociated myelinoids was performed by thresh-
olding each cell in Fiji and using the Sholl analysis plugin (Ferreira et al., 2014). All counts andmeasurements were performed blinded.
Automated analysis of myelin volume
To measure global myelin volume in 3D, a custom module was designed using the MetaXpress software from Molecular Devices.
First, an adaptive threshold was used to segment either MBP or CNP immuno-staining. The Filter Mask tool was then used to remove
objects with a Fiber Breadth > 16 mm, a Fiber Length < 10 mm and an Area < 45 mm2. Objects were then shrunk by 4 pixels and a
subsequent filter step removed objects that had an Elliptical Form Factor < 3.7, Fiber Breadth of > 8 mm and an Intensity Standard
Deviation < 1000. Keep Marked Objects was then used to retain objects from the first Filter Mask that overlaid with the second Filter
Mask of shrunk objects. This step specifically helped remove non-myelin objects including cell bodies and debris. The Find Blobs tool
was used to further identify non-myelin objects with an approximate width between 8-100 mm, which were then enlarged by 5 pixels
and subtracted from the Filter Mask. This step was repeated with blobs approximately 4-6 mm in width. Next, a 3D filter mask was
obtained by connecting neighbouring z-steps using the Connect Touching Objects tool. A final filter step removed 3D objects with a
volume% 450 mm3 and a diameter% 45 mm. In order to measure NF-H intensity, a simple threshold was performed to segment the
total image area, and Connect by Touching was used to segment the total image volume. The volume of segmentedmyelin (mm3) andDevelopmental Cell 56, 1346–1358.e1–e6, May 3, 2021 e5
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Downstream analysis was performed using R-studio to process exported data tables, aggregate measurements for each myelinoid
and normalise data to a batch control.
Statistical analysis
Unless otherwise indicated, data are presented as boxplots showing the medians, interquartile ranges and Tukey-style whiskers that
extend to 1.5 times the interquartile range. Statistical analysis was performed using R-studio and the generalised mixed models plu-
gin glmmTMB (Brooks et al., 2017). For analysis of myelin sheath number and length per cell, nearest neighbour and Sholl
analysis, n = individual cells. For cell counts and global analysis of myelin volume, n = individual myelinoids. Analysis of the proportion
of mature and myelinating oligodendrocytes over time, myelin sheath length and myelin volume over time was performed with time-
point as the fixed effect.Where n = individual cells, individual myelinoids were included as a randomeffect (with random intercepts) as
‘unique myelinoid ID’ to accommodate for clustering of data (Aarts et al., 2014). Analysis of sheath number per cell, mean sheath
length per cell, nearest neighbour (oligodendrocyte density) and Sholl analysis were performed with treatment conditions as fixed
effects and unique myelinoid ID, batch-conversion and cell-line included as random effects. Automated analysis of myelin volume
was performed with treatment as a fixed effect and each batch-conversion of iPSCs included as a random effect. For each exper-
iment, appropriate statistical analyses were made based on the distribution, normality and type of data. Further details and n
numbers for each experiment can be found in the corresponding figure legend. Statistical reporting includes the mean difference be-
tween groups or time-points, 95% confidence interval (95% CI) and p value *p < 0.05, **p < 0.01, ***p < 0.001.e6 Developmental Cell 56, 1346–1358.e1–e6, May 3, 2021
